Paratek Pharmaceuticals (NASDAQ:PRTK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
A number of other research firms have also issued reports on PRTK. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 17th. Robert W. Baird reiterated a “buy” rating and set a $40.00 target price on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. Guggenheim began coverage on shares of Paratek Pharmaceuticals in a report on Tuesday, October 24th. They set a “buy” rating and a $44.00 target price on the stock. BidaskClub lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 2nd. Finally, ValuEngine lowered shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Two analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $39.63.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.93) by $0.16. The company had revenue of $0.01 million for the quarter. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. analysts predict that Paratek Pharmaceuticals will post -3.32 EPS for the current year.
Large investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can purchased a new stake in shares of Paratek Pharmaceuticals in the 3rd quarter valued at approximately $104,000. SG Americas Securities LLC purchased a new stake in shares of Paratek Pharmaceuticals in the 3rd quarter valued at approximately $123,000. Legal & General Group Plc increased its position in shares of Paratek Pharmaceuticals by 13.3% in the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after purchasing an additional 687 shares during the last quarter. Citigroup Inc. increased its position in shares of Paratek Pharmaceuticals by 19,470.0% in the 2nd quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after purchasing an additional 7,788 shares during the last quarter. Finally, Sei Investments Co. increased its position in shares of Paratek Pharmaceuticals by 2,069.3% in the 3rd quarter. Sei Investments Co. now owns 8,981 shares of the specialty pharmaceutical company’s stock valued at $225,000 after purchasing an additional 8,567 shares during the last quarter. 75.05% of the stock is currently owned by institutional investors.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.